Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Reports Q3 revenue $293.8M vs. $270.5M last year. “Through disciplined execution and steady, measurable progress, Emergent’s ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of $2.06. Earnings, adjusted for non-recurring gains, were $1.37 per share. The biopharmaceutical company posted ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million–$274 million. Emergent BioSolutions says its smallpox treatment to be ...

On Monday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $9.67 which represents a slight increase of $0.74 or 8.29% from the prior close of $8.93. The stock opened at $8 ...

My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 ...